Agenus (AGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agenus (AGEN)

AGEN 4.950

-4.1%

2:21 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: StockDung who wrote (98)	12/19/2014 11:12:48 AM
From: Kirk ©	Read Replies (1) of 146

Nice news yesterday for AGEN Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant GlobeNewswire (Thu 7:00AM EST) 7:06 am Agenus announced that its partner GlaxoSmithKline ( GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint ( AGEN) : Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo. The study, which started in August 2010, is a randomized, placebo-controlled, multicenter, international study involving 16,136 adults aged 50 and older. An additional GSK trial to evaluate the ability of HZ/su to prevent shingles is underway in adults aged 70 and older.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next